For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Japan Safety Panels Recognize 1st Death Tied to COVID Vaccine
March 13, 2023
- LDP Lawmakers Call on Local Governments to Urge HPV Vaccinations
March 13, 2023
- Japan to Offer COVID Drugs for Free until September-End
March 13, 2023
- Japan Eager to Resolve Lag in Pediatric Cancer Drug Development: Minister
March 10, 2023
- AbbVie’s Parkinson’s Drug, Kaken’s Eschar Remover Skip March Listing
March 9, 2023
- Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
March 9, 2023
- Paxlovid Priced at 99,027 Yen per 5-Day Treatment; 5% Premium on Lagevrio Price
March 9, 2023
- Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
March 9, 2023
- Tagrisso Faces 10.5% Slash in June in Its Second Re-Pricing
March 9, 2023
- Emgality, Veklury, and More to Get Lower Prices in June: CEA Scheme
March 9, 2023
- LDP League Delivers Proposal on Health Coverage for Patches to Finance Minister
March 9, 2023
- Expert Narukawa Backs JPMA Pitch on Value-Based Pricing, but Disputes Blanket Price Maintenance for Patented Meds
March 8, 2023
- Japan Starts Omicron Vaccine Rollout for Ages 5-11
March 8, 2023
- Japan Panel OKs 2-Dose Regimen for Silgard 9 for Girls below Age 15
March 8, 2023
- AbbVie’s ADC Bags Sakigake Designation in Japan
March 8, 2023
- Japan Cabinet Approves Bill to Create “Japan CDC”
March 8, 2023
- Japan to Lead Discussions on AMR Measures at G7 Summit: PM
March 7, 2023
- Eli Lilly’s UC Drug Mirikizumab in Line for Approval as Early as March
March 6, 2023
- MHLW Calls for Fair-Price Distribution of Drugs Subject to Unprofitability Re-Pricing
March 6, 2023
- SCARDA to Invite Funding Applications for New Modality Research without Requiring PI Plans
March 3, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…